EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function

Pilar Blanco-Lobo, Paula Gilabert-Prieto, Beatriz de Felipe, David Moreno-Fuentes, Paloma Guisado Hernández, Ana Ortiz-Ramírez, Anna Mensa-Vilaró, Juan I Aróstegui, Natalia Palmou, Valle Velasco Gonzalez, Ángela Deyà Martinez, Jan Ramakers und 9 weitere

Journal of Clinical Immunology · 2025

DOI: 10.1007/s10875-025-01957-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Pilar Blanco-Lobo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla, Research Group: "Inborn Errors of Immunity", Pediatric Infectious Diseases, Rheumatology and Immunology Unit, IB…. Hauptthemen laut MEDLINE: Down Syndrome, STAT1 Transcription Factor, Gain of Function Mutation, Janus Kinase Inhibitors. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, University of Seville, Jerome Lejeune Foundation, Instituto de Salud Carlos III, University of Seville, Salud Carlos III, Jerome Lejeune Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Down syndrome (DS) and STAT1 gain-of-function (GOF) share clinical and molecular features, including persistent inflammation. We aimed to investigate whether the coexistence of DS and a STAT1 GOF mutation in a patient synergistically enhances interferon (IFN) signaling and exacerbates inflammatory responses, posing additional management challenges. Two patients (P1 and P2) were studied: P1, with DS and a heterozygous p.P326S STAT1 variant, and P2, with the STAT1 p.P326S variant only. Individuals with isolated DS or STAT1 GOF served as controls. IFN receptor subunits (IFNγR1/R2 and IFNαR1/R2) and responses to IFNα/γ stimulation were analyzed using flow cytometry and RT-PCR. Whole blood type I IFN signature and serum cytokines were evaluated using NanoString and Luminex assays. P1 experienced recurrent infections, chronic mucocutaneous candidiasis, interstitial pneumonitis, and pulmonary hypertension. P2 presented with esophageal candidiasis, dysphagia, and stenosis. The p.P326S variant led to increased STAT1/pSTAT1 levels in response to IFNα/γ. Both patients showed significant clinical improvement with the Janus kinase (JAK) inhibitor ruxolitinib. However, P1's key biomarkers (STAT1 levels, IFN signature, TNFα, IL-6) remained altered, indicating persistent inflammation despite clinical improvement. This first report of a STAT1 GOF variant in DS provides a unique "experiment of nature", offering insights into the interplay between trisomy 21 and STAT1-mediated immune dysregulation. Although ruxolitinib demonstrated clinical benefits, the persistent inflammation observed in P1 highlights the need for further strategies to achieve complete immune resolution. These findings emphasize the importance of comprehensive genetic and immunological assessments in individuals with DS, particularly when immune dysfunction is suspected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeSTAT1 Transcription FactorGain of Function MutationJanus Kinase InhibitorsHumansNitrilesFemaleMalePyrimidinesPyrazolesCytokinesBiomarkers

Stichwörter der Autor:innen

Down syndromeInborn errors of immunityInterferonJAK inhibitorsRuxolitinibSTAT1 gain-of-functionSTAT1 transcription factor

Substanzen

STAT1 Transcription FactorSTAT1 protein, humanNitrilesJanus Kinase InhibitorsruxolitinibPyrimidinesPyrazolesCytokinesBiomarkers

Autor:innen und Institutionen

  • Instituto de Biomedicina de Sevilla, Research Group: "Inborn Errors of Immunity", Pediatric Infectious Diseases, Rheumatology and Immunology Unit, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla…
  • Departamento de Farmacología, Pediatría y Radiología, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.
  • Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío, CSIC/Universidad de Sevilla, Seville, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28009, Madrid, Spain.
  • Departament de Bioquímica i Biomedicina molecular, Facultat de Biologia, Universitat de Barcelona, 08028, Barcelona, Spain.
  • Department of Immunology, CDB, Hospital Clínic Barcelona, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III, University of Seville, Jerome Lejeune Foundation
  • Instituto de Salud Carlos III, University of Seville
  • Salud Carlos III, Jerome Lejeune Foundation

Zitieren

APA

Blanco-Lobo, P., Gilabert-Prieto, P., de Felipe, B., Moreno-Fuentes, D., Guisado Hernández, P., Ortiz-Ramírez, A., Mensa-Vilaró, A., Aróstegui, J. I., Palmou, N., Velasco Gonzalez, V., Deyà Martinez, Á., Ramakers, J., Ivorra-Cortés, J., Roca, C., Cordero, E., Guillen, I., Valerdiz Menéndez, N., Lucena, J. M., Gaboli, M., …, & Neth, O. (2025). Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-025-01957-0

Vancouver

Blanco-Lobo P, Gilabert-Prieto P, de Felipe B, Moreno-Fuentes D, Guisado Hernández P, Ortiz-Ramírez A, et al. Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-025-01957-0

BibTeX
@article{BlancoLobo2025,
  author = {Blanco-Lobo, Pilar and Gilabert-Prieto, Paula and de Felipe, Beatriz and Moreno-Fuentes, David and Guisado Hernández, Paloma and Ortiz-Ramírez, Ana and Mensa-Vilaró, Anna and Aróstegui, Juan I and Palmou, Natalia and Velasco Gonzalez, Valle and Deyà Martinez, Ángela and Ramakers, Jan and Ivorra-Cortés, José and Roca, Cristina and Cordero, Elisa and Guillen, Inmaculada and Valerdiz Menéndez, Nicolás and Lucena, José Manuel and Gaboli, Mirella and Olbrich, Peter and Neth, Olaf},
  title = {Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function},
  journal = {Journal of Clinical Immunology},
  year = {2025},
  doi = {10.1007/s10875-025-01957-0}
}
Kostenlos starten →